Safety of a fixed-dose combination of artesunate and amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in real-life conditions of use in Côte d’Ivoire
Authors:
- Serge-Brice AssiSASerge-Brice Assi
- Yapo Thomas AbaYAYapo Thomas Aba
- Jean Claude YavoJYJean Claude Yavo
- Abouo Franklin NguessanANAbouo Franklin Nguessan
- N’cHo Bertin TchiekoiNTN’cHo Bertin Tchiekoi
- Koffi Moïse SanKSKoffi Moïse San
- Emmanuel BissagnénéEBEmmanuel Bissagnéné
- Stephan DuparcSDStephan Duparc
- Valérie LameyreVLValérie Lameyre
- Mea Antoine TanohMTMea Antoine Tanoh
Open Access
- 3 January 2017
- journal article
- research article
- Published by Springer Nature in Malaria Journal
- Vol. 16 (1) , 8
Abstract
In many malaria-endemic, sub-Saharan African countries, existing pharmacovigilance systems are not sufficiently operational to document reliably the safety profile of anti-malarial drugs. This study describes the implantation of a community-based pharmacovigilance system in Côte d’Ivoire and its use to document the safety of ASAQ Winthrop® (artesunate–amodiaquine). This prospective, longitudinal, descriptive, non-comparative, non-interventional study on the use of artesunate–amodiaquine in real-life conditions of use was conducted in seven Community Health Centres of the Agboville district in Côte d’Ivoire. Twenty trained Health Centre employees and 70 trained community health workers were involved in data collection in the field. All patients with suspected uncomplicated falciparum malaria, seeking treatment at one of the participating Health Centres, and treated with artesunate–amodiaquine could be enrolled. Two visits were planned, one for inclusion at the Health Centre and a second at home, performed by a community health worker 3–10 days after the inclusion visit. Administration of artesunate–amodiaquine was unsupervised. Adverse events (AEs) were documented at the home visit or during any unexpected visit to the Health Centre or to the hospital and coded and adjudicated by a local pharmacovigilance committee. Symptoms suggestive of hepatic failure, severe neutropaenia, extrapyramidal disorders and retinopathy were considered a priori as AEs of special interest. Some 15,228 malaria episodes in 12,198 patients were evaluated; 2545 AEs were documented during 1978 malaria episodes (13.0%). The most frequently observed events were asthenia (682 cases), vomiting (482 cases) and somnolence (174 cases). Most reported AEs were of mild or moderate intensity and resolved without corrective treatment. One-hundred and five (105) AEs reported during 100 episodes (0.7%) were considered as serious. Three serious cases of transient extrapyramidal disorders, identified as AEs of special interest were reported in three patients. The fixed dose artesunate–amodiaquine combination ASAQ Winthrop® for the unsupervised treatment of uncomplicated falciparum malaria under real-life conditions of care in Côte d’Ivoire is well tolerated. The study emphasizes the interest of involving properly trained community health workers to collect pharmacovigilance data in the field in order to document rare AEs.Keywords
Funding Information
- The Medicines for Malaria Venture
- Sanofi
- DNDi
This publication has 32 references indexed in Scilit:
- Usefulness of Plasmodium falciparum-specific rapid diagnostic tests for assessment of parasite clearance and detection of recurrent infections after artemisinin-based combination therapyMalaria Journal, 2013
- Early parasitological response following artemisinin-containing regimens: a critical review of the literatureMalaria Journal, 2013
- Anti-malarial drug safety information obtained through routine monitoring in a rural district of South-Western SenegalMalaria Journal, 2012
- Efficacy of fixed-dose combination artesunate-amodiaquine versus artemether-lumefantrine for uncomplicated childhood Plasmodium falciparum malaria in Democratic Republic of Congo: a randomized non-inferiority trialMalaria Journal, 2012
- Repeated treatment of recurrent uncomplicated Plasmodium falciparum malaria in Senegal with fixed-dose artesunate plus amodiaquine versus fixed-dose artemether plus lumefantrine: a randomized, open-label trialMalaria Journal, 2011
- Exposure to anti-malarial drugs and monitoring of adverse drug reactions using toll-free mobile phone calls in private retail sector in Sagamu, Nigeria: implications for pharmacovigilanceMalaria Journal, 2011
- Innovative public-private partnerships to maximize the delivery of anti-malarial medicines: lessons learned from the ASAQ Winthrop experienceMalaria Journal, 2011
- The efficacy and safety of a new fixed-dose combination of amodiaquine and artesunate in young African children with acute uncomplicated Plasmodium falciparumMalaria Journal, 2009
- Pattern of drug utilization for treatment of uncomplicated malaria in urban Ghana following national treatment policy change to artemisinin-combination therapyMalaria Journal, 2009
- New once a day, fixed dose antimalarial is now available for adults and childrenBMJ, 2007